We are inspired by a vision for the future in which data, computing, networks, and other digital and deep technologies deliver meaningful outcomes and insight for improving health and the provision of care.


We invest in both solutions intended for use in the diagnosis or cure of disease and solutions designed to help healthcare organizations—be them hospitals, biopharmas, insurers, etc.—be better at what they do. 

We see our sweet spot at seeding founders who are marrying in-depth understanding of the complex network of healthcare system participants with meaningful engineering innovation, advanced data science, and information technology-enabled products and services. We look for and invest in founders determined to effectively and efficiently serve these participants on the european continent, where we are based, and internationally.

In our investment criteria and process, we are informed by a Stanford-born methodology of health technology innovation known as Biodesign. Since 2001, Biodesign has proven to de-risk the process of new venture creation by applying a need-driven and value-based approach to reinventing healthcare with the help of technology. To learn more about the methodology, head to The Student Guide to Biodesign, developed by a team of Stanford instructors and students who are passionate about education and making high-quality learning materials available and accessible to all.

We invest in european companies as well as in selected non-european companies with ties to europe. Wherever they are, our goal is to help founders ready their companies to raise series A capital, and to access international markets.


To learn more about our process, click here.


We are committed

to need-driven founders with international ambitions.

Our sweet spot is seed.

We back bold entrepreneurs moved by unmet needs to transform healthcare, through the meaningful application of technology.


We believe europe's growing technology ecosystem has global impact potential.

Barcelona is our home. We invest across the european continent and beyond, motivated by the opportunity to tell success stories of innovation made in europe.

True innovation adds value. We are excited by tech's potential to deliver clinical and economics outcomes. We look for ways to create value across the care continuum and all specialties.


We have a special interest in innovative technology solutions and business models.

We understand the complexity of healthcare.

We connect to ecosystem players to help founders navigate the complex landscape of healthcare stakeholders. Locally, and, by bridging to US markets, methodologies, and KOLs.



We have a bias for teams that are interdisciplinary & diverse along multiple dimensions.

We believe founders building diverse, multidisciplinary teams have higher chance of success. When we invest in teams that are not, we do so with founders' commitment to meet these goals.

We believe in the power of mentorship.

We are a small core team augmented by a network of collaborators, advisors, and venture partners. 

We leverage this network as part of our commitment to help our portfolio founders.



with focus on data, computing, networks,
and other digital, information, and deep technologies


we prefer to invest at the preseed and seed stages,

and follow-on in select portfolio companies as they reach series A readiness


our ground zero is Barcelona,

our goal is to invest across the european continent (including, UK!) and beyond (US, CA, and IL)


we uphold principles of Biodesign in our investment approach,

confident that need-driven technology ventures generate the highest value in healthcare and for their investors